Institute for Translational Medicine and Therapeutics' 2012 symposium be held from Oct. 16-17

The Institute for Translational Medicine and Therapeutics' 7th Annual International Symposium (ITMAT) will be held October 16 and 17 at the Perelman School of Medicine, University of Pennsylvania. This unique gathering brings together international experts to debate opportunities and hazards in systems pharmacology and translational medicine, or how drugs work on specific pathways, variability in patient response and why many treatments fail. Thought leaders from academic medical centers and industry will be speaking on topics including, Global Approaches to Translational Medicine, Translational Therapeutics, The Individualization of Therapy and Systems Pharmacology.

Garret A. FitzGerald, Director of ITMAT, will be hosting the event. He has some great speakers lined up, including:

• David Artis, PhD, Perelman School of Medicine, Department of Microbiology University of Pennsylvania, Translating Immunology: New Insights into the Pathogenesis and Treatment of Chronic Inflammatory Diseases in Humans
• Carl June, MD, Perelman School of Medicine, University of Pennsylvania, Pathology and Laboratory Medicine, Abramson Family Cancer Research Institute, Engineered T cells: muscle CARs and sports CARs for Cancer
• Hal Dietz, MD, Johns Hopkins University School of Medicine, will be presenting Found in Translation: New Insights into the Pathogenesis and Treatment of Marfan Syndrome and Related Disorders
• Peter Schultz, PhD, Department of Chemistry, The Scripps Research Institute, will be speaking on A Chemist's Foray into Translational Research
• Matthias Mann, Director, Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany, will be presenting Proteomics for Systems-Wide Approaches in Cell Line, Animal and Human Systems

The full agenda and list of speakers can be found on ITMAT's website. There will also be opportunities to meet and speak with presenters and fellow attendees, which will include academics and industry executives.